Cotrimoxazole Prophylaxis Therapy Research Articles

Time to viral load suppression and its predictors among people living with HIV on antiretroviral therapy in Gebi Resu zone, Afar Region, Ethiopia, 2023.

This study aimed to estimate the time to viral load suppression and identify its predictors among HIV patients receiving antiretroviral therapy (ART) in the Gebi Resu zone, Afar Region, Ethiopia, 2023. The study was conducted at public health facilities in the Gebi Resu zone of the Afar region. This study is a facility-based, retrospective follow-up study. This study included 298 people living with HIV who were receiving ART services at selected health facilities in the Gebi Resu zone. Data were collected by reviewing patient records using a structured checklist. Bivariate and multivariate Cox regression analyses were conducted to assess the relationship between variables and control for confounders. The incidence rate of viral load suppression was 9.46 per 100 person-months. The median time to viral load suppression was 7.7 months, with an interquartile range of 3.8 months (IQR = 6.47-10.27). Patients at clinical stages 3 and 4 [AHR = 0.67, 95%CI (0.47, 0.96)], those who received cotrimoxazole prophylaxis therapy [AHR = 1.47, 95%CI (1.12, 1.92)], and patients with poor drug adherence [AHR = 0.40, 95%CI (0.18, 0.90)] were significantly associated with time to viral load suppression among people on antiretroviral therapy. The time to viral load suppression and the median time to viral load suppression among people living with HIV on ART were shorter than those observed in many developing and developed countries. Clinical stage, cotrimoxazole prophylaxis therapy, and drug adherence were significant predictors of viral load suppression.

Brief communication: reasons for non-adherence of co-trimoxazole prophylaxis therapy among people living with HIV in a resource-limited setting, Northern Ethiopia

This study aimed to assess the prevalence and reasons for nonadherence to cotrimoxazole prophylaxis therapy. A cross-sectional study was conducted among people living with HIV attending Ayder Comprehensive Specialized Hospital. Data were collected through interviews and reviews of medical records. Binary logistic regression was employed to analyze factors associated with CPT nonadherence. Approximately two-thirds (65.5%) of the participants were non-adherent to co-trimoxazole prophylaxis therapy. The main reasons for non-adherence were side effects, pill fatigue and forgetfulness. Strategies to improve adherence to co-trimoxazole prophylaxis therapy should focus on the combined patient, clinical and medication related issues of people living with HIV.

Determinates of anemia among Human Immune Deficiency Virus positive children on Anti-retro Viral Therapy in selected health facilities, Northwest Ethiopia: A Case-Control Study.

Even though antiretroviral therapy (ART) access for human immunodeficiency virus (HIV)-infected children increased dramatically, anaemia has continued as a challenge regardless of a cluster of differentiation (CD4) count and viral load. Hence, the present study aimed to assess the determinants of iron deficiency anaemia among children living with HIV after the initiation of ART. An institution-based unmatched case-control study was conducted among consecutively selected 712 children on HIV care from 1 September to 30 October 2022 in the Metekel zone. A pre-tested and structured data extraction checklist was used to collect the data. Data were analysed using STATA version 16 software. Binary logistic regression was used to find the association between independent variables and anaemia. The level of statistical significance was declared at a value of P < 0⋅05. A total of 712 HIV-positive children (178 cases and 534 controls) were included in this study, with a completeness rate of 98⋅8 %. In multivariable analysis, variables that have a statistically significant association with anaemia were as follows: CD4 count <350 (Adjusted Odds Ratio [AOR] 2⋅76; 95 % CI 1⋅76, 4⋅34), World Health Organization (WHO) clinical stage III (AOR 7⋅9; 95 % CI 3⋅5, 17⋅91) and stage IV (AOR 7⋅8; 95 % CI 3⋅37, 18⋅1), cotrimoxazole prophylaxis therapy (AOR 0⋅5; 95 % CI 0⋅31, 0⋅8) and mid-upper arm circumference (MUAC) ≤11⋅5 mm (AOR 2⋅1; 95 % CI 1⋅34, 3⋅28). The present study found that CD4 count, WHO clinical stage, cotrimoxazole prophylaxis therapy and MUAC were significantly associated with anaemia in children on ART. Therefore, continuous screening of anaemia and nutritional treatment is essential in these patients.

Survival analysis and predictors of mortality among adult HIV/AIDS patients initiated antiretroviral therapy from 2010 to 2015 in Dubti General Hospital, Afar, Ethiopia: A retrospective cohort study

BackgroundAlthough antiretroviral therapy (ART) is well accepted to increase survival of patients with HIV/AIDS, AIDS related deaths continue to be a major problem in sub-Saharan Africa like Ethiopia. Studies have showed variable findings in the survival status of patients with HIV/AIDS initiating ART, and there was no such study in the study area. Therefore, purpose of this study was to determine the survival and predictors of mortality among HIV/AIDS patients starting taking ART in Dubti General Hospital, Afar, Ethiopia. MethodsA 5 year retrospective cohort study was performed among 702 HIV/AIDS patients aged ≥15 years that started ART between December 31, 2010, and December 31, 2015 in Dubti General Hospital, Afar, Ethiopia. A simple random sampling technique was used to select the study subjects from each WHO stage based stratum. Socio-demographic, clinical and survival status data were extracted by reviewing patients’ records. Data were analyzed by using SPSS Version 21. Kaplan-Meier and Cox-regression models were used to estimate survival, and explore predictors of mortality. Variables with a p value of <0.05 in multivariate Cox regression analysis were considered statistically significant. ResultsAmong 702 study participants, 82 (11.7%) died during follow up, and the overall incidence rate of mortality was 5.81 per 100 person-years. Identified predictors of mortality were being not married (AHR = 3.71, 95% CI: 1.97–6.99), had no formal education (AHR = 2.33, 95% CI: 1.33–4.38), bedridden functional status (AHR = 5.91, 95% CI: 2.71–12.88), advanced WHO stage III and IV (AHR = 4.36, 95% CI: 2.20–8.64), BMI 16–18.4 kg/m2 (AHR = 3.03, 95% CI: 1.50–6.13), and BMI<16.0 kg/m2 (AHR = 5.47; 95% CI: 2.85–10.50), CD4 count ≤50 cells/mm3 (AHR = 6.62, 95% CI: 4.73–8.52), hemoglobin <8 g/dl (AHR = 5.21; 95% CI: 2.64–10.26), not used cotrimoxazole prophylaxis therapy (AHR = 2.78, 95% CI: 1.61–4.73), stavudine based regimen (AHR = 2.34, 95% CI: 1.32–4.13), and zidovudine based regimen (AHR = 2.49, 95% CI: 1.41–4.39). ConclusionHigh mortality was observed in this cohort, and participants with stage III and IV, low CD4 count, low hemoglobin level, bed ridden functional status, low BMI should be closely monitored even with the scarce resources. In addition, the use of cotrimoxazole prophylaxis therapy should be more encouraged to increase survival.

Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia

Tuberculosis (TB) is major public health concern and Isoniazid Preventive Therapy (IPT) helps to prevent TB development among patients living with human immune deficiency virus (PLWHIV). However, the evidence is limited especially in the study area. Therefore, this study aimed to determine the prevalence and factors associated with TB among IPT users and non-IPT users of PLWHIV in Dessie, Ethiopia. A comparative cross-sectional study was employed for1 month in Dessie. A total of 326 respondents were selected using systematic random sampling. Bivariable and multivariable logistic regression analyses were computed to identify factors associated with Tuberculosis. In multivariable analysis, AOR with 95% CI was used to declare statistically significant variables with TB. The prevalence of TB among non-IPT users was 48.5%, (95% CI 40.8–56.2%), and among IPT users was 8%, (95% CI 5–13%). Cotrimoxazole prophylaxis therapy (CPT) (AOR = 5.835, 95% CI 2.565–13.274), IPT (AOR = 10.359, 95% CI 4.054–26.472), ART adherence (AOR = 30.542, 95% CI 12.871–72.475), and believing that IPT use prevents TB (AOR = 0.093, 95% CI 0.018–0.484) were statistically significant factors. The prevalence of TB was higher among non-IPT users than among IPT users. Therefore, efforts should be strengthened to implement widespread use of IPT among adult PLWHIV.

The factors associated with co-trimoxazole hypersensitivity in people living with HIV/AIDS: a retrospective study

Background: Antibiotic adverse drug reactions (ADRs) can occurred during any treatment of infection, especially opportunistic infections in people living with HIV/AIDS (PLWHA). Co-trimoxazole is a sulfonamide fixed dose combination antibiotic, consisted of sulfamethoxazole and trimethoprim which is effective in treatment of several infections and for prophylaxis of pneumocystis jiroveci pneumonia. The universal use of co-trimoxazole for prophylaxis has been shown to decrease hospitalizations, morbidity and mortality among PLWHA, but potentially associated with ADRs include drug hypersensitivity reaction. The objective was to identify factors associated with co-trimoxazole hypersensitivity in PLWHA.Methods: A retrospective study were enrolled 404 participants PLWHA who were received co-trimoxazole due to co-trimoxazole prophylaxis therapy (CPT), between January 2015–December 2018. The independence variables such as age, sex, history of allergy, hypersensitivity reactions, duration of therapy (days), CD4 (cells/µl) and opportunistic infection to co-trimoxazole hypersensitivity reaction were analyzed using spearman test.Results: Mostly of the participants was male: 253 (62.60%). Eighteen (4.50%) with history of allergy, 64 (15.90%) were known co-trimoxazole hypersensitivity reaction. The most frequent clinical manifestation was maculopapular rash: 27 (42.3%), followed by urticaria alone: 17 (26.3%), fixed drug eruption: 12 (19.6%), and angioedema with or without urticaria: 8 (11.8%). The history of allergy, opportunistic infection and duration of treatment were associated factors to co-trimoxazole hypersensitivity reaction.Conclusions: This study was identified, that history of allergy, duration of treatment and opportunistic infection were factors associated with co-trimoxazole hypersensitivity in PLWHA.

Treatment Outcome of Tuberculosis and Associated Factors among TB-HIV Co-Infected Patients at Public Hospitals of Harar Town, Eastern Ethiopia. A five-year retrospective study

BackgroundThe bidirectional relationship between the twin epidemics of Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) causes major global health challenges in the twenty-first century. TB-HIV co-infected people are facing multifaceted problems like high lost to follow up rates, poor treatment adherence, high TB recurrence rate, and high mortality risk. Our objective was to assess the outcomes of TB treatment and associated factors among TB-HIV co-infected patients in Harar town, Eastern part of Ethiopia, 2018.MethodsA retrospective study was conducted among systematically selected 349 TB/HIV co-infected patients who registered from 2012 to 2017 in two public hospitals in Harar town. The data were collected through document review by using a pre-tested structured data extraction checklist. The data were analyzed using SPSS Version 21. Bivariate and multivariate logistic regression were determined at 95% confidence intervals.ResultsAmong the 349 TB/HIV co-infected patients included in the study, 30.1% were cured, 56.7% had completed their treatment, 7.7% died, 1.7% were lost to follow up, and 3.7% were treatment failure. Overall, 86.8% of the TB-HIV co-infected patients had successful TB treatment outcomes. The patients who were on re-treatment category (AOR = 2.91, 95% CI: 1.17–7.28), who had a history of opportunistic infection (AOR = 3.68, 95% CI: 1.62–8.33), and who did not take co-trimoxazole prophylaxis (AOR = 3.54, 95% CI: 1.59–7.89) had 2.91, 3.68, and 3.54 times higher odds of having unsuccessful TB treatment outcome than their counterparties, respectively. The chance of unsuccessful TB treatment outcome was 4.46 (95% CI: 1.24–16.02), 5.94 (95% CI: 1.87–18.85), and 3.01 (95% CI: 1.15–7.91) times higher among TB/HIV patients in stage 2, 3 and 4 than those in stage 1, respectively.ConclusionsThe overall rate of the success of the TB treatment among TB-HIV co-infected patients in this study was higher compared with many previous studies. TB/HIV patients with a history of previous TB treatment, smear-positive pulmonary TB, late HIV stage, history of opportunistic infection and not being on co-trimoxazole prophylaxis therapy were at a high risk of getting poor treatment outcomes.

Incidence of Opportunistic Infections among Adult HIV Positive People Receiving Co-trimoxazole Prophylaxis

In Ethiopia, Co-trimoxazole prophylaxis therapy (CPT) used to prevent opportunistic infections among people living with HIV is the standard of practice; however incidence of opportunistic infection and their predictors are rarely documented in the country. This was a retrospective follow up study to describe the incidence and predictors of opportunistic infections among 244 adults receiving CPT. Participants were followed for a median time of 72 weeks. During a study period a total of 53opportunistic infections were recorded; making the overall incidence rate 23.9/100 person-years. High incidence of opportunistic infections is likely to occur if: the clients were married (adjusted hazard ratio (AHR) 1.965;(95% CI: 1.109, 3.451), had history of tuberculosis treatment (AHR: 2.34(95% CI:1.05, 5.24)), patients who are indicated for CPT because of both clinical and WHO clinical staging criteria(AHR 2.418 (95% CI:1.02, 5.72 ),and had poor adherence to CPT (AHR, 2.11 (95% CI: 1.19-3.72)). Eventhough adherence is non-substitutable strategy to prevent opportunistic infection, the cohort of HIV patients failed to adhere to CPT, which in turn resulthigh incidence of opportunistic infections among them, therefore improving adherence as guideline should be a priority to prevent OIs among people living with HIV in the study region.

Incidence of Opportunistic Infections among Adult HIV Positive People Receiving Co-trimoxazole Prophylaxis

In Ethiopia, Co-trimoxazole prophylaxis therapy (CPT) used to prevent opportunistic infections among people living with HIV is the standard of practice; however incidence of opportunistic infection and their predictors are rarely documented in the country. This was a retrospective follow up study to describe the incidence and predictors of opportunistic infections among 244 adults receiving CPT. Participants were followed for a median time of 72 weeks. During a study period a total of 53opportunistic infections were recorded; making the overall incidence rate 23.9/100 person-years. High incidence of opportunistic infections is likely to occur if: the clients were married (adjusted hazard ratio (AHR) 1.965;(95% CI: 1.109, 3.451), had history of tuberculosis treatment (AHR: 2.34(95% CI:1.05, 5.24)), patients who are indicated for CPT because of both clinical and WHO clinical staging criteria(AHR 2.418 (95% CI:1.02, 5.72 ),and had poor adherence to CPT (AHR, 2.11 (95% CI: 1.19-3.72)). Eventhough adherence is non-substitutable strategy to prevent opportunistic infection, the cohort of HIV patients failed to adhere to CPT, which in turn resulthigh incidence of opportunistic infections among them, therefore improving adherence as guideline should be a priority to prevent OIs among people living with HIV in the study region.

Impact of TB-HIV collaborative activities on case fatality among HIV-infected Tuberculosis patients in Gujarat, INDIA

Background: Tuberculosis (TB) control efforts have been challenged by deadly interaction of TB and HIV (Human Immunodeficiency Virus) epidemics. To address this challenge in India, all TB patients are routinely offered HIV testing and HIV positive TB patients are provided CPT (Cotrimoxazole Prophylaxis Therapy) and ART (Anti-Retroviral Treatment) as part of TB/HIV collaborative activities. Objective: To study the impact of TB/HIV collaborative activities on case-fatality among HIV infected patients with tuberculosis. Methods: All TB registers maintained under National TB programme (RNTCP) in Gujarat were reviewed and data on HIV testing, ART, CPT and TB treatment outcomes were retrieved for all the TB patients registered in 2010. Results: Among 77,839 registered TB patients, 59,638 (75%) were ascertained for HIV status and 2,893 (4%) were HIV infected. Among those HIV infected TB patients, 95% received CPT and 68% received ART during TB treatment. Case fatality among patients who received both CPT and ART was 10% compared to 37% among those didn’t receive both. Conclusion: TB-HIV collaborative activities reduced mortality among HIV infected TB patients under program condition in Gujarat. The programme needs to sustain efforts of collaborative interventions to improve care for such co-infected patients. Moreover, future TB-HIV collaborative efforts should focus on early diagnosis of HIV and TB and prompt initiation of ART. Keywords: TB-HIV collaboration, Case-fatality, RNTCP, ART, CPT, Gujarat

Applying the ICMJE authorship criteria to operational research in low‐income countries: the need to engage programme managers and policy makers

1 Medical Department (Operational Research Unit), Medecins sans Frontieres, Operational Centre Brussels, MSF-Luxembourg, Luxembourg, Luxembourg 2 Department of Molecular and Cellular Interactions, Flemish Institute of Biotechnology, Brussels, Belgium 3 Department of Microbiology, Institute of Tropical Medicine, Antwerp, Belgium 4 Department of Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya 5 Centre for International Health, University of Bergen, Bergen, Norway 6 Center for Operational Research, International Union Against Tuberculosis and Lung Disease, Paris, France 7 International Union Against TB and Lung Disease, Kampala, Uganda 8 Medecins Sans Frontieres, Addis Ababa, Ethiopia 9 International Union Against Tuberculosis and Lung Disease, South East Asia office, New Delhi, India 10 Medecins Sans Frontieres, Somali Mission, Somalia 11 Medecins Sans Frontieres, Bujumbura, Burundi 12 National Institute for Medical Research, Dar Es Salaam, Tanzania 13 National Tuberculosis Control Programme, Harare, Zimbabwe 14 Medecins Sans Frontieres, Capetown, South Africa 15 Medecins Sans Frontieres, Nairobi, Kenya 16 Joint Center for Bioethics, University of Toronto, Toronto, Canada 17 London School of Hygiene and Tropical Medicine, London, UK

Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia

Background: The antiretroviral treatment (ART) scale-up service has been a recent development in Ethiopia, but its impact on mortality has not been well investigated. The aim of this study was to assess the early survival outcome of the scale-up service by utilizing routine hospital data.Methods: All adult HIV/AIDS patients who started on antiretroviral treatment in Shashemene and Assela hospitals from January 1, 2006 to May 31, 2006 were included and followed up for 2 years. Data were extracted from standard patient medical registrations. Kaplan–Meier curves were used to estimate survival probability and the Cox proportional hazard model was applied to determine predictors of mortality. Two alterative assumptions (real case and worst case) were made in determining predictors of mortality.Results: The median age of patients was 33 years and 57% were female. Eighty-five percent had CD4 <200 cells/µL with a median CD4 count of 103 cells/µL. The median survival time was 104.4 weeks. A total of 28 (10.3%) deaths were observed during the 2-year period and 48 patients (18%) were lost to follow up. The majority of deaths occurred in the first 4 months of treatment. In multivariate analysis, 2-year survival was significantly associated with the clinical stage of the disease, baseline hemoglobin, and cotrimoxazole prophylaxis therapy (CPT) at or before ART initiation in both assumptions. The median CD4 count and body weight showed a marked improvement during the first 6 months of treatment, followed by stagnation thereafter.Conclusion: The study has shown an overall low mortality but a high loss to follow-up rate of the cohort. Advanced clinical stage, anemia, low body weight, and lack of CPT initiation were independent predictors of mortality – but not gender. CPT initiation should be encouraged in routine HIV care services, and patient retention mechanisms have to be strengthened. Stagnation in immunological and weight recovery after the first 6 months should be further investigated. The utilization of routine data should be encouraged in order to facilitate appropriate decision making.